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Abstract
Introduction: The Akt pathway plays a central role in regulating cell survival, proliferation and metabolism, and is
one of the most commonly activated pathways in human cancer. A role for Akt in epithelial differentiation,
however, has not been established. We previously reported that mice lacking Akt1, but not Akt2, exhibit a
pronounced metabolic defect during late pregnancy and lactation that results from a failure to upregulate Glut1 as
well as several lipid synthetic enzymes. Despite this metabolic defect, however, both Akt1-deficient and Akt2-
deficient mice exhibit normal mammary epithelial differentiation and Stat5 activation.
Methods: In light of the overlapping functions of Akt family members, we considered the possibility that Akt may
play an essential role in regulating mammary epithelial development that is not evident in Akt1-deficient mice due
to compensation by other Akt isoforms. To address this possibility, we interbred mice bearing targeted deletions in
Akt1 and Akt2 and determined the effect on mammary differentiation during pregnancy and lactation.
Results: Deletion of one allele of Akt2 in Akt1-deficient mice resulted in a severe defect in Stat5 activation during
late pregnancy that was accompanied by a global failure of terminal mammary epithelial cell differentiation, as
manifested by the near-complete loss in production of the three principal components of milk: lactose, lipid, and
milk proteins. This defect was due, in part, to a failure of pregnant Akt1
-/-;Akt2
+/- mice to upregulate the positive
regulator of Prlr-Jak-Stat5 signaling, Id2, or to downregulate the negative regulators of Prlr-Jak-Stat5 signaling,
caveolin-1 and Socs2.
Conclusions: Our findings demonstrate an unexpected requirement for Akt in Prlr-Jak-Stat5 signaling and establish
Akt as an essential central regulator of mammary epithelial differentiation and lactation.
Introduction
The serine/threonine kinase Akt is a critical downstream
effector in multiple signal transduction pathways and
regulates cellular proliferation, survival, and metabolism.
Consistent with this, Akt is inappropriately activated in
a wide range of human cancers [1,2]. Three Akt iso-
forms (Akt1, Akt2, and Akt3) are present in mammals,
and targeted deletion of each gene has revealed distinct
as well as overlapping functions in cellular physiology.
Akt1
-/- mice exhibit increased perinatal mortality and a
modest growth defect. Akt2
-/- m i c ea r ev i a b l eb u t
develop insulin resistance and a diabetes-like phenotype,
whereas Akt3
-/- mice have normal glucose homeostasis
but decreased brain size [3-7].
Given the high degree of homology among Akt iso-
forms, the possibility that these three proteins play
redundant roles has been addressed by generating mice
deficient for multiple isoforms. This has revealed that
Akt1
-/-;Akt2
-/- mice display perinatal lethality, reduced
growth, and defects in skin and bone development, as
well as adipogenesis [8]. Akt1
-/-;Akt3
-/- mice die during
embryonic development at embryonic day 12, and
Akt1
-/-;Akt3
+/- mice exhibit developmental abnormalities
in multiple organs that result in the death of 90% of
mice shortly after birth [9]. In contrast, Akt2
-/-;Akt3
-/-
mice are born in Mendelian ratios, but are significantly
smaller than wild-type littermates [10]. These results
indicate that individual Akt isoforms play both unique
and overlapping roles in development and physiology,
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ity may be required to produce a given cellular output.
Similar to Akt, the Stat5 pathway plays a central role
in regulating cellular function and is activated in
response to a wide range of stimuli, including growth
factors, cytokines, and hormones. Stat5 regulates cell
proliferation, survival, and differentiation through direct
activation of target genes. Stat5 is encoded by two clo-
sely related genes, Stat5a and Stat5b. While constitutive
deletion of both genes leads to embryonic lethality [11],
conditional knockouts have revealed tissue-specific func-
tions of Stat5 [11-14].
The best-characterized role of Stat5 in normal physiol-
ogy is the regulation of pregnancy-induced mammary
epithelial development, where it is essential for the pro-
liferation, differentiation, and survival of mammary
epithelial cells [11]. Analysis of a variety of Stat5 mutant
alleles in mice has revealed that Stat5 deficiency in the
mammary gland leads to a near-complete loss of lobu-
loalveolar development, a reduction in expression of
milk protein genes during pregnancy, and lactation fail-
ure [11,15-18]. Stat5 deletion during pregnancy results
in the death of differentiated mammary epithelial cells,
with further experiments suggesting that the require-
ment for Stat5 is required for the survival of alveolar
luminal progenitor cells during pregnancy-induced lobu-
loalveolar development [11,19].
Constitutive activation of Akt in the mammary epithe-
lium promotes the precocious accumulation of intracel-
lular lipid droplets during pregnancy and delays post-
weaning involution by inhibiting apoptosis [20-22].
Consistent with its upstream role as a negative regulator
of Akt activity, Pten-deficient mice exhibit delayed
mammary involution and reduced apoptosis [23],
whereas forced expression of Pten in the mammary
gland results in impaired lactation due to decreased
mammary epithelial proliferation and increased apopto-
sis during pregnancy [24].
We recently investigated the role of Akt in mammary
development by examining mice bearing targeted dele-
tions in either Akt1 or Akt2 [25]. We found that loss of
both alleles of Akt1 results in failure of the coordinated
metabolic response required for the establishment of
lactation at parturition, including increased glucose
uptake and lipid synthesis, which in turn results in
decreased milk production. In contrast, deletion of both
alleles of Akt2 had no discernible effect on lactation.
Notably, despite the requirement for Akt1 in the meta-
bolic control of the lactating mammary gland, mammary
epithelial differentiation, proliferation, and survival were
unaffected during pregnancy in Akt1
-/- mice.
In light of the overlapping functions of Akt isoforms,
we considered the possibility that Akt may play an
essential role in regulating mammary epithelial
development that is not evident in Akt1
-/- mice due to
compensation by other Akt isoforms. To address this
issue, we interbred mice bearing targeted deletions in
Akt1 and Akt2 in order to determine the effect on mam-
mary differentiation. We find that deletion of one allele
of Akt2 in Akt1
-/- mice results in a severe defect in
terminal mammary epithelial differentiation and lacta-
tion failure due to a loss of prolactin-mediated Stat5
activation. Notably, this defect occurred in the absence
of changes in pregnancy-induced lobuloalveolar develop-
ment, including proliferation, apoptosis or acinar forma-
tion. As such, the defects observed in Akt1
-/-;Akt2
+/-
mice reflect the abrogation of Stat5 signaling and the
molecular program of terminal differentiation in the
mammary gland, a program that is intact in Akt1-
deficient mice. Our observations demonstrate an unex-
pected requirement for Akt in Prlr-Jak-Stat5 signaling in
the mammary gland, and establish Akt as an essential
regulator of differentiation, metabolism and lactation in
the mammary gland.
Materials and methods
Animals
Akt1
-/- and Akt2
-/- mice of C57BL/6 genetic background
were generated and provided by Dr Morris Birnbaum
(Howard Hughes Medical Institute, University of Penn-
sylvania, Philadelphia, PA, USA) [5,6]. Mice were housed
and maintained according to Institutional Animal Use
and Care Committee guidelines. For timed pregnancies,
the morning of the observed virginal plug was counted
as day 0.5. At given time points, animals were killed by
carbon dioxide asphyxiation and the mammary gland
tissues were harvested and snap-frozen on dry ice, fixed
in 4% paraformaldehyde in 1 × PBS (4% paraformalde-
hyde (PFA)) or frozen in Optimal Cutting Temperature
(OCT) compound for further analysis.
The determination of pup weight, milk volume and
pup mortality among various knockout mice has been
described previously [25,26]. All experiments and
experimental methods related to the use of animals
were approved by the University of Pennsylvania Institu-
tional Animal Use and Care Committee.
Antibodies
The following rabbit polyclonal antibodies were used in
the study: phospho-S6 (Ser235/236), S6, and Akt (Cell
Signaling Technology, Danvers, MA, USA), suppressor
of cytokine signaling 2(Socs2) (Zymed Laboratories,
South San Francisco, CA, USA), inhibitor of DNA bind-
ing 2 (Id2) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), and mouse milk-specific proteins (Nordic Immu-
nological Laboratories, Tilburg, Netherlands). The fol-
lowing mouse monoclonal antibodies were used:
phospho-Stat5a/b (Tyr694/Tyr699) and Stat5a/b
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San Ramon, CA, USA), caveolin-1 (BD Biosciences, San
Diego, CA, USA) and Gata-3 (Santa Cruz Biotechnol-
ogy). The goat anti-Elf5 polyclonal antibody was pur-
chased from Santa Cruz Biotechnology.
The rabbit anti-Npt2b polyclonal antibody was gener-
o u s l yp r o v i d e db yD rJ i mT u r n er (National Institute of
Dental and Craniofacial Research, National Institute of
Health, Bethesda, MD, USA). The rat anti-cytokeratin 8
(CK8) was purchased from the Developmental Studies
Hybridoma Bank (University of Iowa, Iowa City, IA,
USA).
Mammary gland whole-mount and histological analysis
The abdominal mammary glands fixed in 4% PFA were
either stained in carmine/aluminum potassium sulfate
for whole mounts as previously described [27] or
embedded in paraffin wax. For histological analysis, 5
μm tissue sections were cut, dewaxed in xylene, rehy-
drated, and stained with H & E.
Immunofluorescence analysis
After paraffin-embedded 5 μm tissue sections were
cleared and rehydrated, sections were subjected to anti-
gen retrieval performed by heating treatment in an anti-
gen unmasking solution (Vector Laboratories,
Burlingame, CA, USA). Subsequently, sections were
incubated in blocking solution consisting of 5% BSA
a n d1 0 %( v / v )n o r m a lg o a ts e r u mi nP B Sa tr o o mt e m -
perature for 1 hour. The primary antibodies phospho-
Stat5 (1:100), Npt2b (1:300) and anti-CK8 (1:100) were
then applied and incubated at 4°C overnight. Appropri-
ate fluorescein-conjugated secondary antibodies (Mole-
cular Probes, Eugene, OR, USA) were applied for 1
hour, counterstained with 5 mg/ml Hoechst 33258
(1:10,000), and mounted with Immu-mount (Thermo
Scientific, Pittsburgh, PA, USA).
Stained sections were examined using a Leica micro-
scope (Model DM5000B; Leica Microsystems, Bannock-
burn, IL, USA) equipped with a mercury lamp and
FITC (L5), Texas Red (TX2) and Hoechst/DAPI (A4) fil-
ter cubes. Images were acquired by a digital camera
(Leica DFC350FX) operated and analyzed with Image-
Pro Express software and processed with the Photoshop
program.
Northern blot, in situ hybridization and quantitative RT-
PCR analysis
Total RNA isolation from snap-frozen abdominal and
inguinal mammary tissues without lymph nodes, pre-
paration of radioactively labeled cDNA probes, northern
blots and in situ hybridization were performed as pre-
viously described [28]. The cDNA probes for northern
hybridization correspond to b-casein (nucleotides 181
to 719), whey acidic protein (WAP) (nucleotides 131 to
483), ε-casein (nucleotides 83 to 637), a-lactalbumin
(nucleotides 174 to 700) and CK18 (nucleotides 589 to
1287). The sequence of an oligomer used to detect 18S
rRNA is CGGAACTACGACGGTATCTG.
Single-stranded cDNA for quantitative RT-PCR analy-
sis was generated by the high-capacity cDNA reverse
transcription kit (Applied Biosystems, Carlsbad, CA,
USA). Quantitative RT-PCR was performed using
the TaqMan-based ABI 7900HT fast real-time PCR sys-
tem according to the manufacturer’s instructions
(Applied Biosystems). The probes used were Aldoc
Mm01298111_g1, Fads1 Mm00507605_m1, Elovl5
Mm00506717_m1, Prlr Mm00599957_m1, and cytokera-
tin 18 Mm01601706_g1.
Western blot analysis
Frozen abdominal and inguinal mammary tissues (lymph
nodes removed) were homogenized in lysis buffer (1%
Triton X-100, 50 mM Tris-HCl, pH 7.4, 150 mM NaCl,
1 mM ethylenediamine tetraacetic acid (EDTA), 50 mM
sodium fluoride (NaF), 3 mM sodium pyrophosphate,
and 5 mM b-glycerolphosphate) supplemented with pro-
tease inhibitor cocktail (Roche, Indianapolis, IN, USA)
and were subjected to western blot analysis, performed
as described previously [25]. The following primary anti-
bodies were used: phospho-S6 (Ser235/236) (1:1,000), S6
(1:1,000), Akt (1:1,000), phospho-Stat5a/b (Tyr694/
Tyr699) (1:500), Stat5a/b (1:500), mouse milk-specific
proteins (1:20,000), b-tubulin (1:1,000), caveolin-1
(1:1,000), Socs2 (1:150), Id2 (1:100), and Elf5 (1:100).
Chemiluminescence was detected with horseradish per-
oxidase-conjugated goat anti-rabbit or mouse secondary
antibodies at a dilution of 1:5,000, and was developed in
the ECL plus system based on the manufacturer’s proto-
col (Amersham Biosciences, Piscataway, NJ, USA) fol-
lowed by exposure to X-ray film (Kodak, Rochester, NY,
USA). All experiments were independently repeated
three times. Only the representative images are shown.
Densitometry for western blots was carried out with the
Photoshop program.
Lactose analysis
Lactose in the mammary gland was measured by sub-
jecting 20 μg tissue lysates to the lactose assay kit as per
the manufacturer’s instructions (MBL, Woburn, MA,
USA). The lactose level was calculated by subtracting
the free galactose level from the total galactose level.
Mammary gland culture
The whole-organ culture of the mammary gland was as
described previously but with slight modifications [26].
Briefly, the lymph node-free abdominal and inguinal
glands of Akt1
+/+;Akt2
+/+ mice and Akt1
-/-;Akt2
+/- mice
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minced into fine pieces (~2 mm). Tissues were incu-
bated in Waymouth’s serum-free medium (Invitrogen,
Carlsbad, CA, USA) supplemented with 20 mM HEPES,
4 mM glutamine, 5 μg/ml insulin, and 1 μg/ml hydro-
cortisone. The tissues were replaced with fresh culture
medium daily to remove hormones carried from mice,
and the mammary tissues were cultured for 5 days fol-
lowed by growth-factor starvation overnight. The tissues
treated with 0.2 μg/ml prolactin for the indicated peri-
ods were collected.
Statistical analysis
Data are presented as the mean ± standard error of the
mean (SEM). Statistical analysis was calculated by Stu-
dent’s t test unless otherwise indicated.
Results
Akt is required for lactation
Homozygous deletion of either Akt1 or Akt2 has no
effect on mammary epithelial cell differentiation [25].
Akt1 is required in an isoform-specific manner, however,
for coordinating multiple metabolic pathways in the
mammary gland during the transition from pregnancy
to lactation [25]. The inability of lactating Akt1
-/- mice
to secrete normal amounts of milk arises from a failure
to upregulate Glut1, glucose uptake, and lipid synthesis,
as well as a failure to downregulate lipid catabolism
[25]. In contrast, Akt2 is entirely dispensable for the
metabolic response of the mammary gland to lactation.
Since Akt1 and Akt2 are expressed in the same cell
types in the mammary gland [25], we considered the
possibility that they might have compensatory roles in
development. As deletion of one Akt3 allele in Akt1-
deficient mice results in perinatal lethality, we generated
mice with combined loss of Akt1 and Akt2 alleles.
Because Akt1
-/-;Akt2
-/- mice die shortly after birth, we
c o m p a r e dt h ea b i l i t yo fAkt1
-/-;Akt2
+/- mice and Akt1
-/-;
Akt2
+/+ mice to support the growth and survival of nur-
sing pups.
In agreement with our previous report [25], pups
nursed by Akt1
-/-;Akt2
+/+ mothers, but not those nursed
by Akt1
+/+;Akt2
-/- mothers, exhibited growth retardation
compared with pups nursed by wild-type mice
(Figure 1a). Deletion of one allele of Akt2 on an Akt1-
deficient background exaggerated the growth defect
observed in pups nursed by Akt1-deficient mice (P <
0.0001). In contrast, deletion of one Akt1 allele on an
Akt2-deficient background had no effect on the ability
of lactating mothers to support pups (Figure 1a). By
postpartum day 4, pups nursed by Akt1
-/-;Akt2
+/- mice
weighed significantly less than those nursed by Akt1
-/-;
Akt2
+/+ mice. By postpartum day 9, the average weight
of pups nursed by Akt1
-/-;Akt2
+/- mothers was two-
thirds that of pups nursed by Akt1
-/-;Akt2
+/+ mothers
and one-half that of pups nursed by Akt1
+/+;Akt2
+/+
mothers (Figure 1a).
In addition to the dramatic growth defect observed in
pups nursed by Akt1
-/-;Akt2
+/- mothers, these pups also
displayed markedly increased perinatal mortality. By
postpartum day 9, 70% of pups nursed by Akt1
-/-;Akt2
+/-
mice had died, compared with 30% of pups nursed by
Akt1
-/-;Akt2
+/+ mice and 2% of pups nursed by wild-type
mice (Figure 1b).
Consistent with the severe growth retardation and
increased mortality of pups nursed by Akt1
-/-;Akt2
+/-
mice, milk production was significantly decreased in
these mice (Figure 1c). Compared with wild-type mice,
Akt1
-/-;Akt2
+/- mice displayed a nine-fold reduction in
oxytocin-stimulated milk secretion (P = 0.0001)
(Figure 1c), a reduction even more profound than the
four-fold reduction observed in Akt1
-/-;Akt2
+/+ mice
(Figure 1c). These observati o n ss u g g e s tt h a tm i l kp r o -
duction in the lactating mammary gland is influenced by
allele dosages of Akt.
Akt is required for mammary differentiation during
pregnancy and lactation
Milk production is the culmination of an orchestrated
series of developmental events. Exposed to the hormonal
milieu of pregnancy and lactation, mammary epithelial
cells proliferate to form alveoli and differentiate into
milk-secreting cells. Akt1
-/-;Akt2
+/+ mice exhibit a lacta-
tion defect, yet mammary glands from these mice
undergo normal alveologenesis and secretory differentia-
tion during pregnancy [25]. Since Akt1
-/-;Akt2
+/- mice
displayed a more severe lactation defect than Akt1
-/-;
Akt2
+/+ mice, we examined alveolar development and
differentiation in these mice.
Examination of carmine-stained whole mounts of
mammary glands harvested from late-term pregnant and
lactating mice revealed a defect in the expansion of
lobuloalveolar structures in Akt1
-/-;Akt2
+/- mice com-
pared with Akt1
-/-;Akt2
+/+ mice or wild-type mice
(Figure 2a). By day 9 of lactation, Akt1
-/-;Akt2
+/- mam-
mary epithelia failed to form fully-expanded alveolar
secretory units (Figure 2a). Analysis of histological sec-
tions revealed that alveoli of Akt1
-/-;Akt2
+/+ mice and
Akt1
-/-;Akt2
+/- mice were markedly less distended with
milk compared with those of wild-type mice from day
18.5 of pregnancy through day 9 of lactation (Figure
2b). By comparison, both Akt1
+/+;Akt2
-/- and Akt1
+/-;
Akt2
-/- mammary epithelia displayed normal alveologen-
esis (Figure 2a,b). Evaluation of mammary sections for
bromodeoxyuridine (BrdU) incorporation and TUNEL
staining revealed normal rates of proliferation and apop-
tosis in Akt1
-/-;Akt2
+/- glands during mid-to-late preg-
nancy (data not shown). This observation suggests that
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-/-;Akt2
+/-
mice is due to defective functional differentiation of
mammary epithelial cells, rather than reduced prolifera-
tion or survival.
The morphological and histological signs of reduced
milk secretion in Akt1
-/-;Akt2
+/- mammary glands sug-
gested that the alveolar epithelia failed to undergo func-
tional differentiation. To determine the differentiation
status of Akt1
-/-;Akt2
+/- mammary epithelia we examined
the expression of milk protein genes. Sequential upregu-
lation of early (b-casein), mid (WAP and a-lactalbumin),
and late (ε-casein) milk protein genes is a hallmark of
secretory differentiation of the mammary epithelium
[27]. Northern analysis of mammary gland mRNA at day
18.5 of pregnancy demonstrated that expression of
b-casein, WAP,a n dε-casein was not altered in Akt1
-/-;
Akt2
+/+ mice or in Akt1
+/+;Akt2
-/- mice. Expression of
these genes was significantly reduced, however, in
Akt1
-/-;Akt2
+/- mice (Figure 3a). Consistent with these
data, immunoblotting analysis revealed markedly reduced
levels of milk proteins in the mammary gland of Akt1
-/-;
Akt2
+/- mice at day 18.5 of pregnancy (Figure 3b).
The failure of mammary glands from Akt1
-/-;Akt2
+/-
mice to express milk proteins suggested a defect in
secretory differentiation. Npt2b, a Na-Pi co-transporter,
is a marker of secretory differentiation and is highly
expressed in the lactating, but not nulliparous, mam-
mary gland [17,25,28,29]. We therefore examined the
expression of Npt2b in mammary tissue from lactating
mice of differing Akt genotypes. Whereas Npt2b expres-
sion was appropriately upregulated in lactating mam-
mary epithelia of wild-type mice, Akt1
-/-;Akt2
+/+ mice,
Figure 1 Deletion of one Akt2 allele in Akt1-deficient mice exacerbates their lactation defect. (a) Postpartum weight gain in pups nursed
by Akt foster mice. Average daily pup weights for litters nursed by Akt1
+/+;Akt2
+/+ mice, Akt1
-/-;Akt2
+/+ mice, Akt1
+/+;Akt2
-/- mice, Akt1
-/-;Akt2
+/-
mice, or Akt1
+/-;Akt2
-/- mice. Statistical analysis was calculated by mixed model with first-order autoregressive covariance structure. (b) Pup
survival in litters nursed by Akt foster mice. Pup survival was defined as the percentage of mice that survived to postpartum day 9. (c) Milk yield
collected from the thoracic and abdominal mammary glands of mice with indicated Akt genotypes at day 9 of lactation after oxytocin
stimulation.
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+/+;Akt2
-/- mice, and Akt1
+/-;Akt2
-/- mice, Npt2b
expression failed to be upregulated in lactating Akt1
-/-;
Akt2
+/- mice (Figure 3d). Notably, total Akt protein
expression was significantly lower in the mammary
glands of Akt1
-/-;Akt2
+/+ mice compared with Akt1
+/+;
Akt2
-/- mice (0.26 ± 0.05 vs. 1.04 ± 0.13; Figure 3b,c),
indicating that Akt1 is the predominant form of Akt in
the mammary gland at day 18.5 of pregnancy. Consis-
tent with this notion, total Akt expression was signifi-
cantly reduced by deletion of one allele of Akt1 in
Akt2
-/- mice (0.71 ± 0.12 for Akt1
+/-;Akt2
-/- mice vs.
1.04 ± 0.13 for Akt1
+/+;Akt2
-/- mice), but not by deletion
of one allele of Akt2 in Akt1
-/- mice (0.29 ± 0.04 for
Akt1
-/-;Akt2
+/- mice vs. 0.26 ± 0.05 for Akt1
-/-;Akt2
+/+
mice) (Figure 3b,c). Taken together, these results indi-
cate that the severe lactation defect observed in Akt1
-/-;
Akt2
+/- mice is caused by defective secretory differentia-
tion of the mammary gland due to a complete lack of
Akt1 in conjunction with partial loss of Akt2.
Akt regulates the production of essential milk
components in the lactating mammary gland
Milk is a complex mixture of proteins, lipids and carbo-
hydrates [30]. Our finding that milk protein expression
is reduced in Akt1
-/-;Akt2
+/- mice (Figure 3a,b), together
with our previous finding that Akt1 is required for lipid
synthesis during lactation [25], led us to examine poten-
tial roles for Akt in the biosynthesis of each of the three
components of milk.
The cellular capacity for protein synthesis is regu-
lated by the mammalian target of rapamycin (mTOR)
pathway. The decrease in milk proteins observed in
Akt1
-/-;Akt2
+/- mammary glands could be due to the
observed decreases in steady-state levels of transcrip-
tion for milk protein genes (Figure 3a), or due to
decreased mRNA expression coupled with decreased
rates of translation for milk proteins. To address this
issue, we examined levels of phospho-S6, a direct
downstream target of the mTOR pathway, in the late
Figure 2 Akt1
-/-;Akt2
+/- mice exhibit defective expansion of mammary gland during late pregnancy and lactation. (a) Whole-mount
carmine-stained mammary glands from Akt1
+/+;Akt2
+/+ mice, Akt1
-/-;Akt2
+/+ mice, Akt1
-/-;Akt2
+/- mice, Akt1
+/+;Akt2
-/- mice, and Akt1
+/-;Akt2
-/- mice
at day 18.5 of pregnancy and days 2 and 9 of lactation. (b) H & E-stained sections of mammary glands from mice with indicated Akt genotypes
at day 18.5 of pregnancy (top) and day 9 of lactation (bottom). Scale bars: (a) 2 mm, (b) 100 μm.
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significantly reduced in the mammary glands of Akt1
-/-
;Akt2
+/- mice compared with either wild-type mice (P
< 0.001) or Akt1
-/-;Akt2
+/+ mice (P = 0.03), indicating
that mTOR activity is decreased in the Akt1
-/-;Akt2
+/-
mammary gland (Figure 3b,c).
Lactose in mammary alveolar cells is synthesized from
glucose and galactose by the lactose synthase complex,
which consists of a-lactalbumin and galactosyltransfer-
ase [31]. In Akt1
-/-;Akt2
+/+ m a m m a r yt i s s u e ,am o d e s t
decrease in intraepithelial lactose levels was evident (Fig-
ure 3e), presumably due to reduced glucose uptake
coupled with normal levels of a-lactalbumin (Figure 3a)
[25]. In contrast, lactose levels were dramatically
reduced in Akt1
-/-;Akt2
+/- mice during lactation, reflect-
ing decreased glucose uptake coupled with a marked
Figure 3 Akt1
-/-;Akt2
+/- mice exhibit impaired secretory epithelial differentiation during late pregnancy and lactation. (a) Northern
analysis of milk protein gene expression in mammary glands from pregnant mice (day 18.5) with the indicated Akt genotypes. Cytokeratin 18
(CK18) and 18S rRNA were included as controls for epithelium-specific expression and RNA loading, respectively. WAP, whey acidic protein. (b)
Representative western analysis of mammary glands from mice with the indicated Akt genotypes at day 18.5 of pregnancy. Protein lysates were
immunoblotted with the indicated antibodies. b-Tubulin levels served as a loading control. (c) Quantitative analysis of Akt/b-tubulin and
phospho-S6 (p-S6)/S6 in late-pregnant mice (n = 6 mice per genotype). The ratios were normalized to Akt1
+/+;Akt2
+/+ mice. Statistical analysis in
differential expression was calculated by comparing each group with Akt1
+/+;Akt2
+/+ mice, except for the indicated P values shown between
Akt1
-/-;Akt2
+/+ mice and Akt1
-/-;Akt2
+/- mice. *P < 0.001. n.s., not significant. (d) Immunofluorescence analysis of Na-Pi cotransporter 2B (Npt2b)
expression during lactation. Mammary sections from lactating mice with indicated Akt genotypes were immunostained for Npt2b (green). Nuclei
were counterstained with Hoechst 33258 (blue). Luminal epithelial cells were counterstained with CK8 (red). Mammary gland tissue from a 6-
week-old virgin MTB mouse served as a negative control for staining. Scale bar: 100 μm. (e) Lactose levels of mammary tissues from Akt1
+/+;Akt2
+/+ mice, Akt1
-/-;Akt2
+/+ mice, and Akt1
-/-;Akt2
+/- mice at day 9 of lactation (n = 4 for each genotype).
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= 0.03 compared with wild-type mice and Akt1
-/-;
Akt2
+/+ mice, respectively) (Figure 3a,e).
We previously showed that Akt1 contributes to
lipid biosynthesis in the lactating mammary gland by
regulating expression of genes involved in lipid
metabolism, such as Scd2, Scd3 and Dgat2 [25]. To
extend this analysis, we examined expression of
Aldoc, Fads1 and Elovl5, which are preferentially
expressed in the mammary epithelium, are upregu-
lated during lactation and have been implicated in
fatty acid synthesis [32]. Quantitative RT-PCR analy-
sis demonstrated that the expression levels of Aldoc,
Fads1 and Elovl5 were lower in Akt1
-/-;Akt2
+/+ mice
compared with wild-type mice, and were further
reduced in Akt1
-/-;Akt2
+/- mice (Figure 4). In aggre-
gate, these findings demonstrate that Akt is required
for production of the three main components of
milk - milk proteins, lipid, and lactose - in the lac-
tating mammary gland.
Akt is required for Stat5 activation
The Prlr-Jak2-Stat5 signaling pathway plays a critical
role in alveolar morphogenesis and differentiation
[11,16,18,33,34], as illustrated by the fact that Stat5-defi-
cient mice fail to form alveoli during pregnancy and do
not express milk protein genes [17]. Although alveolar
formation in Akt1
-/-;Akt2
+/- mice occurred normally, the
defect in mammary epithelial differentiation observed in
Akt1
-/-;Akt2
+/- mice led us to hypothesize that a func-
tional relationship mighte x i s tb e t w e e nt h eA k ta n d
Stat5 pathways.
To address this hypothesis, we evaluated Stat5 activity
in the mammary glands of Akt1
-/-;Akt2
+/- pregnant mice
by determining the fraction of epithelial cells with
nuclear phospho-Stat5a/b. Mammary tissue was har-
vested from mice with various Akt genotypes at day 18.5
of pregnancy and immunofluorescence was performed
for phospho-Stat5a/b and cytokeratin 8. This revealed
that the fraction of mammary epithelial cells with
nuclear phospho-Stat5a/b was markedly diminished dur-
ing pregnancy in Akt1
-/-;Akt2
+/- mice compared with
Akt1
-/-;Akt2
+/+ mice, Akt1
+/+;Akt2
-/- mice, Akt1
+/-;Akt2
-/-
mice, or wild-type mice (Figure 5a,b). The percentage of
mammary epithelial cells with nuclear phospho-Stat5a/b
was 10-fold lower in Akt1
-/-;Akt2
+/- mice compared with
wild-type mice or Akt1
-/-;Akt2
+/+ mice (P <0 . 0 0 0 1a n d
P = 0.0007, respectively). Consistent with this, immuno-
blotting revealed markedly decreased levels of phospho-
Stat5a/b in the mammary glands of pregnant Akt1
-/-;
Akt2
+/- mice (Figure 5c,d). In contrast, phospho-Stat5a/
b levels were unaffected by deletion of Akt1 or Akt2
alone (Figure 5c,d).
Of note, phospho-Stat5 levels were decreased in
Akt1
+/-;Akt2
-/- mice, although not to the extent observed
in Akt1
-/-;Akt2
+/- mice as normalized phospho-Stat5
levels in Akt1
+/-;Akt2
-/- mice remained ~60% higher
than in their Akt1
-/-;Akt2
+/- counterparts (Figure 5d).
Interestingly, despite the modest decreases in phospho-
Stat5 levels observed in Akt1
+/-;Akt2
-/- mice by western
blotting, the fraction of alveolar epithelial cells exhibit-
ing nuclear phospho-Stat5 observed by immunofluores-
cence was unaffected in these mice (Figure 5b,d).
Consistent with the nuclear localization of phospho-
Stat5 representing the most reliable indicator of its
functional status as a transcription factor, milk produc-
tion, milk protein gene expression, mTOR activity,
Npt2b upregulation, and expression of lipid synthetic
enzymes were all normal in Akt1
+/-;Akt2
-/- mice. As
such, the normal nuclear localization and function of
Figure 4 Expression of lipid synthetic enzymes is markedly decreased in Akt1
-/-;Akt2
+/- mice. Relative expression of Aldoc, Fads1 and Elovl5
mRNA in mammary glands from Akt knockout mice at day 9 of lactation (n = 4 for each genotype). Average expression values normalized to
cytokeratin 18 ± standard error of the mean are shown. Statistical differences in expression were calculated by comparing each group with Akt1
+/+;
Akt2
+/+ mice except the indicated P values shown between Akt1
-/-;Akt2
+/+ mice and Akt1
-/-;Akt2
+/- mice. *P < 0.05. **P < 0.01. ***P < 0.001.
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Page 8 of 14Figure 5 Stat5a/b activation is reduced in the mammary glands of Akt1
-/-;Akt2
+/- mice. (a) Immunofluoresence analysis of phospho-Stat5a/
b (p-Stat5) expression in mammary tissues from day 18.5 pregnant mice with the indicated Akt genotypes. Luminal epithelial cells and nuclei
were counterstained with anti-CK8 (green) and Hoechst 33258 (blue), respectively. Scale bars represent 50 μm. (b) Quantitative analysis of
nuclear p-Stat5 in mammary epithelial cells of late pregnant mice (n = 3 mice per genotype). Statistical analysis in differential activity was
calculated by comparing each group with Akt1
+/+;Akt2
+/+ mice, except for the indicated P value shown between Akt1
-/-;Akt2
+/+ mice and Akt1
-/-;
Akt2
+/- mice. *P < 0.0001. (c) Representative western analysis of p-Stat5a/b and total Stat5a/b expression in mammary tissues from day 18.5
pregnant mice with indicated Akt genotypes. b-Tubulin levels served as a loading control. (d) Quantitative analysis of p-Stat5/Stat5 in late-
pregnant mice (n = 6 mice per genotype). The ratio was normalized to Akt1
+/+;Akt2
+/+ mice. Statistical analysis in differential activity was
calculated by comparing each group with Akt1
+/+;Akt2
+/+ mice, except for the indicated P values shown between Akt1
-/-;Akt2
+/+ mice and Akt1
-/-;
Akt2
+/- mice. *P < 0.001. (e) Relative expression of Prlr mRNA in mammary glands from Akt knockout mice at day 18.5 of pregnancy (n = 4 for
each genotype). Average expression values normalized to cytokeratin 18 ± standard error of the mean are shown.
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Page 9 of 14phospho-Stat5 in Akt1
+/-;Akt2
-/- mice despite modest
reductions in total phospho-Stat5 levels could reflect a
threshold requirement forA k tf o rp h o s p h o - S t a t 5
nuclear localization, effects of Akt deletion on phospho-
Stat5 levels in the adipose stroma, or the intriguing pos-
sibility that Akt may affect the nuclear localization of
Stat5 by mechanisms other than its activation by
phosphorylation.
Quantitative RT-PCR analysis revealed that that Prlr
expression in Akt1
-/-;Akt2
+/- mice was comparable with
that observed in wild-type mice (Figure 5e). This indi-
cates that reduction in Stat5 activity in Akt1
-/-;Akt2
+/-
mice is not due to a defect in prolactin receptor expres-
sion. Together, these findings demonstrate that Akt is
required for Stat5a/b activation in the mammary gland
during pregnancy.
Akt regulates the expression of regulators of prolactin-
Jak-Stat5 signaling
A number of molecules have been identified that regu-
late activity of the Prlr-Jak-Stat5 pathway. For example,
caveolin-1 and Socs2 function as suppressors of prolac-
tin-induced phosphorylation of Stat5a/b in mammary
epithelial cells, whereas Id2 positively regulates Stat5a/b
signaling [35-39]. Id2 is also essential for mammary
gland development during pregnancy and lactation
[37,38]. In addition, recent experiments have demon-
strated that Elf5 expression in the mammary epithelium
can rescue the alveolar defect observed in Prlr
-/- mice
and can drive pregnancy-associated mammary differen-
tiation [35,40].
To elucidate the basis of the requirement for Akt in
Prlr-Jak-Stat5 signaling, we examined levels of
caveolin-1, Socs2, and Id2 in day 18.5 pregnant glands
from mice bearing targeted deletions in Akt1 and Akt2.
This analysis revealed that expression of the negative
regulators of Stat5 signaling, caveolin-1 and Socs2, were
markedly increased in Akt1
-/-;Akt2
+/- mice, whereas
expression of the positive regulator of Stat5 signaling,
Id2, was markedly decreased compared with genetic
controls (Figure 6a,b). In contrast, Elf5 expression was
unaffected in Akt1
-/-;Akt2
+/- mice, despite their severe
lactation defect (Figure 6a,b). In addition, although ani-
mal-to-animal variation was evident (Figure 6a), caveo-
lin-1, Socs2 and Id2 levels did not differ between
wild-type mice and Akt2-deficient mice (Figure 6b).
Consistent with a causal relationship between changes
in the expression of Stat5 regulatory molecules and
changes in phospho-Stat5 levels, expression of caveolin-
1 and Socs2 were highest - and expression of Id2 was
lowest - in Akt1
-/-;Akt2
+/- mice compared with other
genotypes (Figure 6a). Changes in caveolin-1, Socs2 and
Id2 expression were not observed in Akt1
+/-;Akt2
-/-
mice, however, despite modest reductions in phospho-
Stat5 levels. This suggests the possibility that additional
regulatory molecules downstream of Akt may play a
role in modulating Prlr-Jak2-Stat5 signaling.
To address the hypothesis that Akt-mediated
decreases in caveolin-1 and Socs2 expression, along with
increases in Id2 expression, are required for prolactin-
induced Stat5a/b activation and mammary differentia-
tion during pregnancy, we evaluated the extent of pro-
lactin-induced Stat5a/b activation in vitro in mammary
glands harvested from Akt1
+/+;Akt2
+/+ mice and Akt1
-/-;
Akt2
+/- mice at day 18.5 of pregnancy. Intact mammary
tissues were used instead of isolated mammary epithelial
cells since dissociation of the mammary gland results in
loss of caveolin-1 expression (unpublished observations),
despite the fact that caveolin-1 is highly expressed in
both the mammary epithelium and adipocytes of the vir-
gin mammary gland [39]. This observation suggests that
the architecture of the mammary gland is important in
maintaining caveolin-1 expression, which is in turn con-
sistent with our observation that mammary epithelial
cell lines express only low levels of caveolin-1 compared
with the mammary gland (unpublished observations).
Addition of prolactin to organ cultures containing
mammary tissue from Akt1
-/-;Akt2
+/- mice or Akt1
+/+;
Akt2
+/+ mice revealed that peak levels of Stat5a/b activa-
tion in Akt1
-/-;Akt2
+/- glands were less than one-half of
those observed in wild-type mice (Figure 6c). These
results indicate that prolactin-induced Stat5a/b activa-
tion in the pregnant mammary gland is markedly
blunted in Akt1
-/-;Akt2
+/- mice. In aggregate, these find-
ings suggest that Akt potentiates prolactin-induced
Stat5a/b activation and mammary epithelial differentia-
tion, at least in part by downregulating the known sup-
pressors of Stat5a/b phosphorylation, caveolin-1 and
Socs2, and by upregulating the positive regulator of
Stat5a/b signaling, Id2.
Discussion
The prolactin-Jak-Stat5 pathway has long been recog-
nized as a central mediator of pregnancy-induced lobu-
loalveolar development and lactation, which together
constitute a developmental transition that is essential for
the survival of mammals. Accordingly, the role of this
pathway in mammary development has been intensively
studied. In the present manuscript we describe a pre-
viously unrecognized requirement for Akt in Prlr-Jak-
Stat5 signaling. Mice lacking one allele of Akt2 and both
alleles of Akt1 displayed a severe lactation defect due to
the global impairment of alveolar epithelial cell differen-
tiation. Consistent with their failure to terminally differ-
entiate, pregnant Akt1
-/-;Akt2
+/- mice fail to upregulate
Npt2b or phospho-Stat5a/b and display markedly
reduced synthesis of each of the three major compo-
nents of milk during lactation. Notably, epithelial cell
Chen et al. Breast Cancer Research 2010, 12:R72
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Page 10 of 14proliferation, cell survival and the formation of architec-
turally normal acini during pregnancy were unaffected
by Akt deletion, reinforcing that the lactation defect
observed in Akt
-/-;Akt2
+/- mice results from a defect in
differentiation, rather than from a failure to form acinar
structures. In aggregate, these findings establish an
essential but heretofore unrecognized role for Akt in
epithelial differentiation.
Despite the fact that both Akt1
-/-;Akt2
+/+ mice and
Akt1
-/-;Akt2
+/- mice exhibit defects in lactation, the
molecular basis of their lactation phenotypes is strik-
ingly different. The isoform-specific defect in lactation
observed in Akt1-deficient mice occurs in the absence of
defects in differentiation and results from a defect in
metabolism [25]. This metabolic defect is due to the
failure of Akt1-deficient mammary epithelial cells to
upregulate key Akt1 target genes, most notably the glu-
cose transporter Glut1 and three lipid synthetic enzymes
Acly, Scd2, and Scd3. These molecular defects result in a
profound inability of terminally differentiated mammary
epithelial cells to take up glucose or to synthesize nor-
mal amounts of lipid. Nevertheless, mammary epithelial
differentiation is normal in lactating Akt1
-/- mice, as
demonstrated by physiologically normal levels of Stat5
activation, normal upregulation of the terminal differen-
tiation marker Npt2b, normal downregulation of the vir-
gin-specific transporter NKCC1, normal expression of
all major milk proteins, and normal intraepithelial lac-
tose levels.
In contrast, our current study demonstrates that dele-
tion of one allele of Akt2 in Akt1-deficient mice results
in a severe defect in mammary epithelial differentiation
that is due to a failure to activate Stat5. In contrast to
Akt1-deficient mice, late-pregnant Akt1
-/-;Akt2
+/- mice
exhibit dramatically reduced Prlr-Jak-Stat5 signaling, as
well as markedly reduced milk protein expression,
Figure 6 Akt regulates the expression of key regulators of Stat5 activity. (a) Representative western analysis of expression of proteins that
regulate mammary differentiation. Mammary protein lysates from mice with indicated Akt genotypes at day 18.5 of pregnancy. b-Tubulin levels
served as a loading control. (b) Quantitative analysis of individual molecule expression in late-pregnant mice (n = 6 mice per genotype). The
ratios in each group were normalized to Akt1
+/+;Akt2
+/+ mice. Statistical analysis was calculated by comparing each group with Akt1
+/+;Akt2
+/+
mice, except for the indicated P values shown between Akt1
-/-;Akt2
+/+ mice and Akt1
-/-;Akt2
+/- mice. *P < 0.05. **P < 0.01. ***P < 0.001. n.s., not
significant. (c) Representative western analysis of Stat5a/b activation in Akt1
+/+;Akt2
+/+ and Akt1
-/-;Akt2
+/- mammary tissues at day 18.5 of
pregnancy treated with prolactin (0.2 μg/ml) for the indicated periods (top panel). Graph shows the ratios of phospho-Stat5 (p-Stat5)/Stat5 at the
indicated timepoints calculated from three independent experiments (bottom panel).
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Page 11 of 14lactose levels, lipid synthesis, expression of the terminal
differentiation marker Npt2b, and mTOR activity.
The lactation defect observed in Akt1
-/- mice is thus
due to a metabolic defect that results from a failure to
upregulate Glut1 and other Akt1-specific target genes.
This defect occurs in the context of normal Prlr-Jak-
Stat5 signaling and normal mammary epithelial differen-
tiation. In contrast, the lactation defect in Akt1
-/-;Akt2
+/-
mice is due to a profound defect in mammary epithelial
differentiation that results from a failure to activate
Stat5. While the outward phenotypes (that is, lactation
defect) of Akt1
-/- mice and Akt1
-/-;Akt2
+/- mice are simi-
lar at a superficial level, the molecular phenotypes as
well as the molecular basis for these phenotypes are
profoundly different.
The defect in Stat5 activation observed in Akt1
-/-;
Akt2
+/- mice is due, at least in part, to a failure to upre-
gulate the positive regulator of Prlr-Jak-Stat5 signaling,
Id2, or to downregulate the negative regulators of pro-
lactin-Jak2-Stat5 signaling, caveolin-1 and Socs2. In
addition, our findings suggest that Akt most likely regu-
lates the expression or activity of other molecules that
modulate Prlr-Jak-Stat5 pathway activity. Together,
these findings provide a molecular basis for this pre-
viously unrecognized connection between the Akt and
Stat5 pathways.
Notably, mammary epithelial proliferation and apopto-
sis rates were unaffected in Akt1
-/-;Akt2
+/- mice during
pregnancy, suggesting that Akt is essential for Stat5-
dependent secretory differentiation of mammary epithe-
lium, but possibly not for Stat5-dependent alveolar
development or acinar formation; that is, whereas Stat5-
deficiency in the mammary gland results in a failure of
lobuloalveolar development as well as secretory differen-
tiation, Akt1
-/-;Akt2
+/- mice exhibit only a defect in
secretory differentiation. Nevertheless, it is possible that
deletion of all four Akt1 and Akt2 alleles would result in
a defect in prolactin-Stat5-mediated epithelial prolifera-
tion and, thereby, lobuloalveolar development similar to
that observed in Stat5-deficient mice. Given the perina-
tal lethality of combined germline deletion of Akt1 and
Akt2, however, mammary-specific deletion of these
genes may be required to determine the role of the
remaining Akt2 allele in mammary epithelial prolifera-
tion and differentiation.
Elf5 has been shown recently to regulate alveolar cell
differentiation by acting downstream of the prolactin
receptor [41]. Since Elf5 expression was unchanged in
the mammary glands of Akt1
-/-;Akt2
+/- mice despite
their dramatic reduction in Stat5 activity, our data sug-
gest that the impact of Akt deletion on Prlr-Jak-Stat sig-
naling is not mediated by Elf5. Rather, our findings
suggest that Akt and Elf5 may act via parallel pathways,
that Elf5 alone is not sufficient to compensate for loss
of Prlr signaling, and that factors other than Prlr signal-
ing may regulate Elf5 [19,41].
Maroulakou and colleagues have reported that Akt1
deficiency delayed, whereas Akt2 deficiency facilitated,
mammary epithelial differentiation during pregnancy
and lactation [42]. In contrast, consistent with our prior
study, the findings described here confirm that deletion
of either Akt1 or Akt2 alone has no appreciable effect
on secretory differentiation during pregnancy or lacta-
tion. Moreover, our finding that deletion of one allele of
Akt2 in Akt1-deficient mice results in a pronounced
defect in mammary epithelial differentiation that is not
observed in mice deficient for Akt1 alone strongly sug-
gests that Akt2 synergizes with - rather than antagonizes
- the pro-differentiation effects of Akt1 on mammary
epithelial cells. Whether this discrepancy is explained by
the mixed genetic background of mice used in the for-
mer study or other factors remains to be determined.
Conclusions
As we have previously described, Akt1 is required for
the orchestrated metabolic response of the mammary
gland to lactation. We now report that the combined
action of Akt1 and Akt2 is required for mammary
epithelial differentiation during pregnancy and lactation
due to their requirement for Stat5 activation. Together,
our findings establish Akt as an essential and central
regulator of epithelial differentiation and metabolism
during lactation. As Akt is a common downstream
effector of many receptor tyrosine kinases, the finding
that the Akt and Stat5 signaling pathways are function-
ally interconnected has important implications for the
numerous biological processes regulated by these path-
ways. In particular, both pathways regulate cell survival
and cell proliferation, and have been implicated in mam-
mary tumorigenesis in rodents and in humans [43-45].
Consequently, our findings predict that therapeutic
blockade of the Akt pathway may be effective in treating
Prlr-Jak-Stat5-driven tumors, whereas blockade of Prlr-
Jak-Stat5 signaling may be effective in treating Akt-dri-
ven tumors. In light of the fact that normal pathways of
differentiation and development are frequently usurped
during the process of carcinogenesis, we predict that
combined therapeutic approaches targeting crosstalk
between the Akt and Prlr-Jak-Stat5 pathways may be
particularly effective in the case of breast cancer.
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